SNPHF Stock Chart & Stats
$11.58
$0.00(0.00%)
At close: 4:00 PM EDT
$11.58
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$8.79 - $14.75
Previous CloseN/A
Volume4.47K
Average Volume (3M)0.00
Market Cap
$3.61B
Enterprise Value$637.18K
Total Cash (Recent Filing)$78.26B
Total Debt (Recent Filing)$31.01B
Price to Earnings (P/E)14.6
Beta-0.27
Next Earnings
Nov 05, 2026EPS Estimate
0.17Next Dividend Ex-DateN/A
Dividend Yield2.3%
Share Statistics
EPS (TTM)119.09
Shares Outstanding322,290,160
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.62
Price to Book (P/B)1.97
Price to Sales (P/S)2.01
P/FCF Ratio15.96
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$15.95Price Target Upside37.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.78
Revenue Forecast (FY)$1.98B
Bulls Say, Bears Say
Bulls Say
Profitability RecoveryThe strong rebound in profitability provides evidence that Santen’s operating model can generate attractive earnings after the 2023 downturn. Healthy EBIT and EBITDA margins should support reinvestment in ophthalmology research, product launches, and commercial expansion over the next several quarters.
Conservative Balance SheetVery low leverage gives Santen meaningful financial flexibility as it funds research, launches medicines, and expands internationally. A substantial equity base also reduces dependence on debt financing, helping the company absorb earnings variability while preserving capacity for strategic investment.
Specialized Ophthalmology PlatformSanten’s focused ophthalmology platform combines research, development, manufacturing, and commercialization in a defined therapeutic area. Its portfolio across glaucoma, dry eye, allergic conjunctivitis, and other conditions can support recurring product sales and lifecycle-management opportunities.
Bears Say
Weaker Cash ConversionAlthough cash generation remains positive, the decline from 2024–2025 levels indicates weaker conversion of accounting earnings into cash. Operating cash flow at about half of EBIT also suggests that working-capital or other operating effects could constrain internally funded investment.
Earnings VolatilityThe 2023 net loss and weak operating margin show that Santen’s earnings trajectory has not been consistently stable. Even with the current recovery, this history indicates that profitability can fluctuate materially, making future earnings less predictable than those of steadier peers.
Uneven Revenue TrajectoryRecent TTM growth is encouraging, but the preceding annual revenue declines point to an uneven top-line trajectory. Sustaining growth will require continued success from new ophthalmic medicines, lifecycle extensions, and geographic expansion rather than relying only on established products.
Santen Pharmaceutical Co News
SNPHF FAQ
What was Santen Pharmaceutical Co Ltd’s price range in the past 12 months?
Santen Pharmaceutical Co Ltd lowest stock price was $8.79 and its highest was $14.75 in the past 12 months.
What is Santen Pharmaceutical Co Ltd’s market cap?
Santen Pharmaceutical Co Ltd’s market cap is $3.61B.
When is Santen Pharmaceutical Co Ltd’s upcoming earnings report date?
Santen Pharmaceutical Co Ltd’s upcoming earnings report date is Nov 05, 2026 which is in 50 days.
How were Santen Pharmaceutical Co Ltd’s earnings last quarter?
Santen Pharmaceutical Co Ltd released its earnings results on Aug 06, 2026. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.133 by $0.007.
Is Santen Pharmaceutical Co Ltd overvalued?
According to Wall Street analysts Santen Pharmaceutical Co Ltd’s price is currently Undervalued.
Does Santen Pharmaceutical Co Ltd pay dividends?
Santen Pharmaceutical Co Ltd pays a Semiannually dividend of $0.136 which represents an annual dividend yield of 2.3%. See more information on Santen Pharmaceutical Co Ltd dividends here
What is Santen Pharmaceutical Co Ltd’s EPS estimate?
Santen Pharmaceutical Co Ltd’s EPS estimate is 0.17.
How many shares outstanding does Santen Pharmaceutical Co Ltd have?
Santen Pharmaceutical Co Ltd has 322,290,160 shares outstanding.
What happened to Santen Pharmaceutical Co Ltd’s price movement after its last earnings report?
Santen Pharmaceutical Co Ltd reported an EPS of $0.14 in its last earnings report, beating expectations of $0.133. Following the earnings report the stock price went up 0.809%.
Which hedge fund is a major shareholder of Santen Pharmaceutical Co Ltd?
Currently, no hedge funds are holding shares in SNPHF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Santen Pharmaceutical Co Ltd
Santen Pharmaceutical Co., Ltd. is a global enterprise engaged in the research, development, manufacturing, and marketing of both pharmaceutical products and medical devices. The company's primary focus lies in ophthalmic solutions, addressing a variety of eye conditions. Its pipeline for glaucoma and ocular hypertension includes several key assets: DE-111, currently in Phase III clinical trials; DE-117, available for sale in Japan; DE-126, progressing through Phase IIb trials; DE-128, which is on the market in Europe and undergoing Phase II/III trials in the United States; and DE-130A, also in Phase III development. Beyond glaucoma, Santen's offerings extend to other ocular ailments. It provides DE-114A for allergic conjunctivitis and DE-076C for vernal keratoconjunctivitis. Furthermore, DE-109 is in Phase III clinical trials for the treatment of uveitis. The company is also active in addressing myopia with DE-127, currently in Phase II/III trials in Japan and Phase III in other Asian markets, alongside STN1013400, which is in Phase I trials. For dry eye, Santen offers DE-089C, which has successfully concluded its Phase III clinical trials. In addition to its prescription portfolio, the company produces and sells various over-the-counter (OTC) pharmaceutical products. Founded in 1890 under the name Santendo Pharmaceutical Co., Ltd., the company rebranded to its current name, Santen Pharmaceutical Co., Ltd., in 1958. It is headquartered in Osaka, Japan.
SNPHF Stock 12 Month Forecast
Average Price Target
$15.95
▲(37.75% Upside)
Technical Analysis
Astellas Pharma
―
Menicon Co
―
Nipro
―
Tsubota Laboratory Incorporated
―
Japan Eyewear Holdings Co.,Ltd.
―
Ownership Overview
―
Insiders
6.53% Mutual Funds
― Other Institutional Investors
85.86% Public Companies and
Individual Investors